Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9258509 | 0.98 | USP2 (0.50) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL14128879 | 0.85 | USP2 (0.34) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL24230295 | 0.77 | USP2 (0.32) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL8318502 | 0.77 | USP2 (0.45) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL1843862 | 0.76 | ALDH1A1 (0.30) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL2351774 | 0.76 | ALDH1A1 (0.48) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL980620 | 0.76 | USP2 (0.56) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL17583500 | 0.76 | USP2 (0.56) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL4048080 | 0.76 | USP2 (0.56) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL671851 | 0.76 | USP2 (0.56) | USP2ALDH1A1LMNACYP1A2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3900715-A1 | SYNERGISTIC ADMIXTURES OF GABAPENTIN AND KETOPROFEN, PHARMACEUTICAL COMPOSITIONS AND THEIR MEDICAL USE | Dompe' Farmaceutici S.P.A. (IT) | 2021-10-27 | — | — | EP | disclosed |
| EP-2897600-B1 | TREATMENT OF MOTOR NEURONOPATHIES | CENTRE NATIONAL DE LA RECHERCHE SCIENT (C N R S ) (FR) | 2018-01-31 | — | — | EP | disclosed |
| US-20110306600-A1 | NOVEL THERAPEUTIC COMPOUNDS | GRUNENTHAL GMBH (DE) | 2011-12-15 | — | — | US | disclosed |
| EP-1404324-B2 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | XENOPORT INC (US) | 2011-04-06 | — | — | EP | disclosed |
| EP-2196201-A2 | Combination of an alpha-2-delta ligand with a pdev inhibitor or a muscarinic antagonist to treat lower urinary tract symptoms | Warner-Lambert Company LLC (US) | 2010-06-16 | — | — | EP | disclosed |
| US-7442834-B2 | Process suitable for industrial scale production of gabapentin | ZHEJIANG CHIRAL MEDICINE CHEMICALS CO., LTD. (CN) | 2008-10-28 | — | — | US | disclosed |
| WO-2008103319-A2 | COMPOUNDS AND METHODS FOR USE IN DETECTING GABAPENTIN | ARK DIAGNOSTICS, INC. (US) | 2008-08-28 | — | — | WO | disclosed |
| US-20080188562-A1 | 1-{[ alpha -isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid and 3-{[( alpha -isobutanoyloxyethoxy)carbonyl]aminomethyl}-5-methyl hexanoic acid; extended oral release dosage form with a reduced rate of systemic clearance and without significant side effects | XENOPORT, INC. | 2008-08-07 | — | — | US | disclosed |
| WO-2004089289-A2 | TREATING OR PREVENTING HOT FLASHES USING PRODRUGS OF GABA ANALOGS | XENOPORT, INC. (US) | 2004-10-21 | — | — | WO | disclosed |
| WO-2003070237-A1 | COMBINATIONS OF AN ALPHA-2-DELTA LIGAND WITH A SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2 | WARNER-LAMBERT COMPANY LLC (US) | 2003-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188562-A1 | 1-{[ alpha -isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid and 3-{[( alpha -isobutanoyloxyethoxy)carbonyl]aminomethyl}-5-methyl hexanoic acid; extended oral release dosage form with a reduced rate of systemic clearance and without significant side effects | GABRB1, GABBR1, GABRB2 | USP2 1005/4885ALDH1A1 148/4885LMNA 3308/4885 |
| US-20110306600-A1 | NOVEL THERAPEUTIC COMPOUNDS | NLN, CLN6, INA | USP2 2895/4885ALDH1A1 917/4885LMNA 3726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.